0 CHECKOUT

Sarcopenia - Pipeline Review, H2 2015

  • ID: 3404568
  • July 2015
  • 62 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Myos Corporation
  • Neurotune AG
  • Novartis AG
  • PolyNovo Limited
  • MORE

Sarcopenia - Pipeline Review, H2 2015

Summary

The report ‘Sarcopenia - Pipeline Review, H2 2015’, provides an overview of the Sarcopenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Myos Corporation
  • Neurotune AG
  • Novartis AG
  • PolyNovo Limited
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Sarcopenia Overview

Therapeutics Development

Pipeline Products for Sarcopenia - Overview

Pipeline Products for Sarcopenia - Comparative Analysis

Sarcopenia - Therapeutics under Development by Companies

Sarcopenia - Therapeutics under Investigation by Universities/Institutes

Sarcopenia - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Sarcopenia - Products under Development by Companies

Sarcopenia - Products under Investigation by Universities/Institutes

Sarcopenia - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Myos Corporation

Neurotune AG

Novartis AG

PolyNovo Limited

PsiOxus Therapeutics Limited

Regeneron Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sarcopenia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AOD-9604 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ARM-210 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bimagrumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BIO-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BIO-103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Espindolol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NEP-28 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NT-1654 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Proteins for Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein for Sarcopenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

S-107 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

trevogrumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sarcopenia - Recent Pipeline Updates

Sarcopenia - Dormant Projects

Sarcopenia - Discontinued Products

Sarcopenia - Product Development Milestones

Featured News & Press Releases

Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models

Dec 14, 2011: Calzada Announces New Applications For AOD9604

Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference

Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia

Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Sarcopenia, H2 2015

Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2015

Sarcopenia - Pipeline by Myos Corporation, H2 2015

Sarcopenia - Pipeline by Neurotune AG, H2 2015

Sarcopenia - Pipeline by Novartis AG, H2 2015

Sarcopenia - Pipeline by PolyNovo Limited, H2 2015

Sarcopenia - Pipeline by PsiOxus Therapeutics Limited, H2 2015

Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015

Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Sarcopenia Therapeutics - Recent Pipeline Updates, H2 2015

Sarcopenia - Dormant Projects, H2 2015

Sarcopenia - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Sarcopenia, H2 2015

Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

GlaxoSmithKline Plc
Myos Corporation
Neurotune AG
Novartis AG
PolyNovo Limited
PsiOxus Therapeutics Limited
Regeneron Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S